Johnson & Johnson Reports Phase 3 extension Data for Trastuzumab in Endometrial cancer

Johnson & Johnson today announced Phase 3 extension results for trastuzumab in patients with endometrial cancer. The study demonstrated that trastuzumab demonstrates durable remissions compared to standard of care or placebo. These results provide important insights into the treatment of endometrial cancer and support the continued development of trastuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.